Advanced delivery carriers should be developed for targeted Nodal silencing therapy and novel therapeutic strategies for CRC using Nodal inhibitors alone or in combination with ferroptosis inhibitors should be developed. The gene discussed is NODAL; the disease is colorectal carcinoma.